发给老马备查:9 _) o, h' j" X; s( H* I
滴水察海(69304838) 15:23:23* q) M6 T) i& @* u9 X: J- r
老马,我看到培美和S-1都提到TS低表达,而鳞多半不是低表达,是不是S-1不靠谱; o; y, j" U" M6 U1 z
吉非替尼和S-1连用的依据( q: w0 {6 B$ s+ B3 j7 H. L' x
Gefitinib induced down-regulation of thymidylate synthase and E2F-1 in gefitinib-resistant NSCLC cells with MET amplification but not in those harboring the T790M mutation of EGFR. The combination of 5-fluorouracil and gefitinib synergistically inhibited the proliferation of cells with MET amplification, but not that of those with the T790M mutation of EGFR, in vitro.# Z# c; ]) B' A; C u
是不是说因C-MET引起的耐药中,吉非替尼会引导TS低表达
( v# a( ~5 p: @& h) y! {) K这样是不是推理出,耐药后,可以用S-1和培美了?7 V, v% H3 \' h# T+ ^
结论:% s) @4 l) Q+ d, q( e; \2 C- A
如果是T790M突变引起的耐药,则2992有效,如果是C-MET扩增引起的突变,则除了184,还可以特+S1联用,而且可能可以用培美。 |